These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31456910)

  • 21. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A predictive probability interim design for phase II clinical trials with continuous endpoints.
    Liu M; Dressler EV
    Stat Med; 2018 May; 37(12):1960-1972. PubMed ID: 29611211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interpreting a Bayesian phase II futility clinical trial.
    Beall J; Cassarly C; Martin R
    Trials; 2022 Nov; 23(1):953. PubMed ID: 36414953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.
    Saville BR; Connor JT; Ayers GD; Alvarez J
    Clin Trials; 2014 Aug; 11(4):485-493. PubMed ID: 24872363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal predictive probability designs for randomized biomarker-guided oncology trials.
    Zabor EC; Kaizer AM; Pennell NA; Hobbs BP
    Front Oncol; 2022; 12():955056. PubMed ID: 36561534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing interim analysis timing for Bayesian adaptive commensurate designs.
    Wu X; Xu Y; Carlin BP
    Stat Med; 2020 Feb; 39(4):424-437. PubMed ID: 31799737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When inferiority meets non-inferiority: implications for interim analyses.
    Bratton DJ; Williams HC; Kahan BC; Phillips PP; Nunn AJ
    Clin Trials; 2012 Oct; 9(5):605-9. PubMed ID: 22796636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.
    Duputel B; Stallard N; Montestruc F; Zohar S; Ursino M
    Stat Methods Med Res; 2023 May; 32(5):963-977. PubMed ID: 36919403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint.
    Adrion C; Mansmann U
    BMC Med Res Methodol; 2012 Sep; 12():137. PubMed ID: 22962944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian predictive approach to interim monitoring in clinical trials.
    Dmitrienko A; Wang MD
    Stat Med; 2006 Jul; 25(13):2178-95. PubMed ID: 16007570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trial monitoring via a futility criterion for interim results on a count data endpoint and a continuous endpoint.
    Quan H; Kang T; Fan C; Lu X; Chen X; Luo X; Wei L
    Contemp Clin Trials; 2021 Apr; 103():106316. PubMed ID: 33571688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
    Barrado LG; Burzykowski T
    Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of futility monitoring guidelines using completed phase III oncology trials.
    Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
    Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes.
    Zhou M; Tang Q; Lang L; Xing J; Tatsuoka K
    Stat Med; 2018 Jun; 37(14):2187-2207. PubMed ID: 29664214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
    Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
    Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.